Reading a preclinical wound-healing model and its relevance to a human tendon

On the subject in the title: Reading a preclinical wound-healing model and its relevance to a human tendon Working notes rather than a conclusion.

I have seen PIONEER 6 (N Engl J Med, 2019) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually shows.

My reading is that the trial is sound for its own question and is being stretched to answer a different one. I might be wrong about that, which is why this is a topic rather than a correction.

What I would like from this discussion: someone who disagrees with me to say why, with the section of the paper they are relying on.

TB-500 is usually the 7-residue actin-binding fragment of thymosin beta-4, not the full 43-residue protein. The two are routinely conflated in supplier documentation and in the literature. Evidence about the full protein does not automatically apply to the fragment.

This follows post #6 rather than contradicting it.

What would change the position on repair peptides: adequately powered, published, peer-reviewed randomised controlled human trials with pre-specified outcomes. That is the standard applied to every other therapeutic claim on this site and it is the standard applied here.

This follows post #11 rather than contradicting it.

The absence of adequately powered published randomised human trials is the central fact about BPC-157. This site states that plainly rather than hedging. Mechanistic plausibility does not substitute for it.

Picking up post #51: that is the part I would want checked first.

Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no excuse for an unverified identity on this compound.

On post #55 — agreed on the reasoning, with one qualification.

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

Why plausible mechanism is not evidence of effect: a mechanism that is chemically or biologically plausible can fail in practice for dozens of reasons — bioavailability, off-target effects, metabolism, clearance, or simply that the mechanism does not do what the theory predicts in a living system. Plausibility is necessary for hope but not sufficient for evidence.

Analytical identity of BPC-157: a 15-residue peptide with an unambiguous mass (≈1419.5 Da). Identity confirmation by LC-MS is trivially easy, which means there is no excuse for an unverified identity on this compound.

Coming back to post #134, because the follow-up matters more than the original answer.

Publication patterns in the BPC-157 literature: a large proportion of the evidence comes from one research group. That is not necessarily wrong — one group can do excellent work — but it is worth noting when evaluating the breadth of support for a claim.